Interleukin 8, a Biomarker to Differentiate Guillain-Barre Syndrome From CIDP

Conclusion CSF IL-8 levels can help to differentiate AIDP variant of GBS from CIDP, including acute-onset CIDP, with high specificity and PPV. This may improve early and appropriate treatment. Classification of Evidence This study provides Class II evidence that CSF IL-8 levels accurately distinguish patients with GBS from those with CIDP.

http://nn.neurology.org/cgi/content/short/8/5/e1031?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - June 17, 2021 Category: Neurology Authors: Breville, G., Lascano, A. M., Roux-Lombard, P., Vuilleumier, N., Lalive, P. H. Tags: Autoimmune diseases, Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy Article Source Type: research